Autres langues Cassava Sciences, Inc.

Actions

SAVA

US14817C1071

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 22/05/2024			Varia. 5j.	Varia. 1 janv.
22,12 ^USD	-0,67 %		-3,87 %	-1,73 %

17/05	CASSAVA SCIENCES, INC. : HC Wainwright persiste à l'achat	ZM
10/05	Cassava Sciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam	13/05
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam	10/05
Cassava Sciences Raises More Than $125 Million From Warrant Distribution	08/05
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution	08/05
North American Morning Briefing : Stock Futures -2-	06/05
Cassava Sciences : Warrants – Notice of Guaranteed Delivery	02/05
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	01/05
North American Morning Briefing : Investors Brace -2-	29/04
Cassava Sciences : Corporate Presentation – Second Quarter 2024	24/04
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	16/04
Redemption Date Announced for Warrants	15/04
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	29/03
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	27/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	27/03
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25/03
Cassava Sciences : Corporate Presentation – First Quarter 2024	25/03
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	25/03
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25/03
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	21/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cassava Sciences, Inc.

Actions

SAVA

US14817C1071

Autres langues

Filtres